US 12,233,062 B2
Heterocyclic derivatives useful as SHP2 inhibitors
Huifeng Han, Beijing (CN); Panliang Gao, Beijing (CN); Cunbo Ma, Beijing (CN); and Di Kang, Beijing (CN)
Assigned to Jacobio Pharmaceuticals Co., Ltd., Beijing (CN)
Filed by Jacobio Pharmaceuticals Co., Ltd., Beijing (CN)
Filed on Feb. 29, 2024, as Appl. No. 18/591,753.
Application 18/591,753 is a continuation of application No. 18/215,381, filed on Jun. 28, 2023, abandoned.
Application 18/215,381 is a continuation of application No. 17/985,399, filed on Nov. 11, 2022, abandoned.
Application 17/985,399 is a continuation of application No. 17/714,547, filed on Apr. 6, 2022, abandoned.
Application 17/714,547 is a continuation of application No. 17/280,573, abandoned, previously published as PCT/CN2019/108181, filed on Sep. 26, 2019.
Claims priority of application No. PCT/CN2018/107492 (WO), filed on Sep. 26, 2018.
Prior Publication US 2024/0285617 A1, Aug. 29, 2024
Int. Cl. A61K 31/497 (2006.01); A61K 31/438 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/4985 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 417/04 (2006.01); C07D 471/10 (2006.01); C07D 487/04 (2006.01); C07D 491/107 (2006.01); C07D 495/10 (2006.01); C07D 513/04 (2006.01); C07D 513/10 (2006.01); C07D 519/00 (2006.01)
CPC A61K 31/497 (2013.01) [A61K 31/438 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/4985 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 417/04 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 491/107 (2013.01); C07D 495/10 (2013.01); C07D 513/04 (2013.01); C07D 513/10 (2013.01); C07D 519/00 (2013.01); C07B 2200/05 (2013.01)] 11 Claims
 
1. A compound of Formula II:

OG Complex Work Unit Chemistry
II;
or a pharmaceutically acceptable salt thereof;
wherein:
custom character represents a single bond or a double bond;
ring A is

OG Complex Work Unit Chemistry
ring B is

OG Complex Work Unit Chemistry
wherein * represents the connection point to G and ** represents the connection point to N;
G is S;
T is CR1R2;
each of R1 and R2 is independently selected from hydrogen, deuterium, or —NH2;
p is 1;
each of R3 and R4 is independently hydrogen or deuterium;
q is 1;
W is absent;
Y5 is C;
Y6 is C;
ring C is

OG Complex Work Unit Chemistry
Ra is H; and
n is 0.